March 8th 2022
By The Center for Biosimilars
Teva’s launch makes it the first competitor to Revlimid in the United States, but perhaps not the last.
March 3rd 2022
By Skylar Jeremias
Releuko, a filgrastim biosimilar developed by Kashiv Biosciences and Amneal Pharmaceuticals, has received FDA approval, the first of 2022.
February 23rd 2022
Tuznue, which references Roche’s Herceptin, is currently under review for marketing authorization by the EU European Medicines Agency, Canada, and South Korea.
February 21st 2022
By Laura Joszt
A report from AHIP found 3 drugs that have multiple biosimilars available can be delivered more affordably through specialty pharmacies.
February 19th 2022
By Gianna Melillo
Coherus released its earnings report for the last quarter of 2021 and for the year as a whole.
February 8th 2022
By Mary Caffrey
The year 2022 “is set to be a turning point” in the United States, as biosimilars are on their way to delivering $133 billion in aggregate savings by 2025, according to Cardinal Health's “2022 Biosimilars Report: The U.S. Journey and Path Ahead.”
February 3rd 2022
Health Canada approves Ontruzant, the fifth Samsung Bioepis biosimilar to be approved for the Canadian market.
February 1st 2022
By Deana Ferreri, PhD
The authors noted that “all biologic therapeutics can be immunogenic or elicit an immune response,” and that an assessment of immunogenicity is part of the totality of evidence required for regulatory approval of biosimilars.
January 26th 2022
US biosimilar uptake faces several barriers, including misconceptions regarding biosimilar efficacy and a misalignment of prescription incentives between payers, providers, and patients, panelists discussed.
January 24th 2022
By Tony Hagen
Sean McGowan, senior director of Biosimilars for AmerisourceBergen, forecasts potential biosimilar approvals and launches in 2022 as well as offers insights into how emerging biosimilars will impact the market and pricing in the coming years during an interview.
